Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey
Ruben A. Mesa(Atrium Health Wake Forest Baptist), John Mascarenhas(Tisch Hospital), James K. Mangan(UC San Diego Health System), Shreekant Parasuraman(Incyte (United States)), Maureen Thyne(Cornell University), David Dubinski(Incyte (United States)), Xiaomei Ma(Yale University), Dilan Paranagama(Incyte (United States)), John Boyle(Ocean Institute), Ahmad Naim(Incyte (United States)), Salman Fazal(Allegheny Health Network), Sara Goldberger(Cancer Support Community), Carole B. Miller(Saint Agnes Hospital), Wendy Wilson(Fred Hutch Cancer Center)
Cited by 91
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Chronic Granulomatous Disease: Report on a National Registry of 368 Patients
|Medicine|2000|1.7k
Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell Transplantation
|Journal of Clinical Oncology|2001|682
Estimating Survival in Patients With Lung Cancer and Brain Metastases
|JAMA Oncology|2016|655